{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:30:49Z","timestamp":1789731049388,"version":"4.0.1"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.pupt.2024.102319","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T04:44:36Z","timestamp":1724993076000},"page":"102319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lipid nanoparticles for pulmonary fibrosis: A comprehensive review"],"prefix":"10.1016","volume":"87","author":[{"given":"Tushar Kanti","family":"Dhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayak","family":"Khawas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelima","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pupt.2024.102319_bib1","doi-asserted-by":"crossref","first-page":"L590","DOI":"10.1152\/ajplung.00221.2016","article-title":"Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis","volume":"311","author":"O'Dwyer","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"7","key":"10.1016\/j.pupt.2024.102319_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.pupt.2024.102319_bib3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1513\/AnnalsATS.201610-764OC","article-title":"Code-based diagnostic algorithms for idiopathic pulmonary fibrosis. Case validation and improvement","volume":"14","author":"Ley","year":"2017","journal-title":"Annals of the American Thoracic Society"},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/ars.2007.1897","article-title":"The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis","volume":"10","author":"Bringardner","year":"2008","journal-title":"Antioxidants Redox Signal."},{"issue":"9","key":"10.1016\/j.pupt.2024.102319_bib5","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1164\/rccm.2202054","article-title":"Pro: inflammatory mechanisms are a minor component of the pathogenesis of idiopathic pulmonary fibrosis","volume":"165","author":"Gauldie","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.pupt.2024.102319_bib6","doi-asserted-by":"crossref","first-page":"L527","DOI":"10.1152\/ajplung.00298.2002","article-title":"Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis","volume":"285","author":"Xu","year":"2003","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"6","key":"10.1016\/j.pupt.2024.102319_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/MAJ.0b013e31821a9d8e","article-title":"Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction","volume":"341","author":"Zoz","year":"2011","journal-title":"Am. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1513\/pats.200601-003TK","article-title":"Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers","volume":"3","author":"Selman","year":"2006","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.pupt.2024.102319_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1513\/pats.201112-055AW","article-title":"The genetic and environmental causes of pulmonary fibrosis","volume":"9","author":"Macneal","year":"2012","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.trsl.2011.01.012","article-title":"MicroRNAs in idiopathic pulmonary fibrosis","volume":"157","author":"Pandit","year":"2011","journal-title":"Transl. Res. : J. Lab. Clin. Med."},{"issue":"11","key":"10.1016\/j.pupt.2024.102319_bib11","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1016\/S0021-9258(18)32345-7","article-title":"Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization","volume":"258","author":"Assoian","year":"1983","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1172\/JCI114808","article-title":"Platelet-derived growth factor in idiopathic pulmonary fibrosis","volume":"86","author":"Antoniades","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0049-3848(00)00237-1","article-title":"Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis","volume":"99","author":"Fujii","year":"2000","journal-title":"Thromb. Res."},{"issue":"2 Pt 1","key":"10.1016\/j.pupt.2024.102319_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1164\/ajrccm.156.2.9608094","article-title":"Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis","volume":"156","author":"Imokawa","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1699-0463.1999.tb01524.x","article-title":"Mechanisms for pro matrix metalloproteinase activation","volume":"107","author":"Murphy","year":"1999","journal-title":"APMIS : APMIS"},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1006\/excr.2000.5125","article-title":"uPA\/plasmin system-mediated MMP-9 activation is implicated in bronchial epithelial cell migration","volume":"264","author":"Legrand","year":"2001","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.pupt.2024.102319_bib17","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bjp.0703137","article-title":"Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro","volume":"129","author":"Gandossi","year":"2000","journal-title":"Br. J. Pharmacol."},{"issue":"153","key":"10.1016\/j.pupt.2024.102319_bib18","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0021-2019","article-title":"The therapy of idiopathic pulmonary fibrosis: what is next?","volume":"28","author":"Somogyi","year":"2019","journal-title":"Eur. Respir. Rev. : an official journal of the European Respiratory Society"},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"11","key":"10.1016\/j.pupt.2024.102319_bib21","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1007\/s13346-022-01148-z","article-title":"Bioavailability enhancement of vitamin E TPGS liposomes of nintedanib esylate: formulation optimization, cytotoxicity and pharmacokinetic studies","volume":"12","author":"Kala","year":"2022","journal-title":"Drug delivery and translational research"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48593-4","article-title":"Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis","volume":"9","author":"Kato","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pupt.2024.102319_bib23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jconrel.2022.10.045","article-title":"Inhaled deep eutectic solvent based-nanoemulsion of pirfenidone in idiopathic pulmonary fibrosis","volume":"352","author":"Kang","year":"2022","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/0970-2113.92361","article-title":"Pulmonary drug delivery strategies: a concise, systematic review","volume":"29","author":"Patil","year":"2012","journal-title":"Lung India : official organ of Indian Chest Society"},{"issue":"5","key":"10.1016\/j.pupt.2024.102319_bib25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2012.09.038","article-title":"Cancer nanomedicines: so many papers and so few drugs","volume":"65","author":"Venditto","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.pupt.2024.102319_bib27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10311-018-00841-1","article-title":"Nanocarriers for drug delivery applications","volume":"17","author":"Chamundeeswari","year":"2019","journal-title":"Environ. Chem. Lett."},{"key":"10.1016\/j.pupt.2024.102319_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2020.07.011","article-title":"Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery","volume":"326","author":"Shen","year":"2020","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/nano9040638","article-title":"Lipid-based nanoparticles: application and recent advances in cancer treatment","volume":"9","author":"Garc\u00eda-Pinel","year":"2019","journal-title":"Nanomaterials"},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib30","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Research in pharmaceutical sciences"},{"key":"10.1016\/j.pupt.2024.102319_bib31","first-page":"1","article-title":"Liposomes as potential drug carrier systems for drug delivery","volume":"1","author":"\u00c7a\u011fda\u015f","year":"2014","journal-title":"Application of nanotechnology in drug delivery"},{"issue":"23","key":"10.1016\/j.pupt.2024.102319_bib32","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.1039\/C8CS00162F","article-title":"Liposomes and polymersomes: a comparative review towards cell mimicking","volume":"47","author":"Rideau","year":"2018","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-4157(98)00006-9","article-title":"Phases and phase transitions of the phosphatidylcholines","volume":"1376","author":"Koynova","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.pupt.2024.102319_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jconrel.2019.03.003","article-title":"Liposomes for delivery of antioxidants in cosmeceuticals: challenges and development strategies","volume":"300","author":"Van Tran","year":"2019","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2024.102319_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000445116","article-title":"Liposomes delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications","volume":"25","author":"Rudokas","year":"2016","journal-title":"Med. Princ. Pract. : international journal of the Kuwait University, Health Science Centre"},{"key":"10.1016\/j.pupt.2024.102319_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2019.05.043","article-title":"Local inflammation alters the lung disposition of a drug loaded pegylated liposomes after pulmonary dosing to rats","volume":"307","author":"Haque","year":"2019","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"key":"10.1016\/j.pupt.2024.102319_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jconrel.2017.03.392","article-title":"Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: challenges and outcomes","volume":"254","author":"Gaber","year":"2017","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/21691401.2014.953633","article-title":"Application of liposomes in medicine and drug delivery","volume":"44","author":"Daraee","year":"2016","journal-title":"Artif. Cell Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib40","first-page":"80","article-title":"Solid lipid nanoparticles: a review","volume":"2","author":"Sathali","year":"2012","journal-title":"Sci Rev Chem Commun"},{"issue":"Suppl 8","key":"10.1016\/j.pupt.2024.102319_bib41","first-page":"32","article-title":"Solid lipid nanoparticles for the delivery of pharmaceutical actives","volume":"9","author":"Loxley","year":"2009","journal-title":"Drug Delivery Technology"},{"issue":"1\u20132","key":"10.1016\/j.pupt.2024.102319_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2008.06.028","article-title":"Development of SLNs from natural lipids: application to topical delivery of tretinoin","volume":"363","author":"Mandawgade","year":"2008","journal-title":"International journal of pharmaceutics"},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib43","first-page":"8","article-title":"Solid lipid nanoparticles-a review","volume":"5","author":"Yadav","year":"2013","journal-title":"Int. J. Appl. Pharm."},{"issue":"3","key":"10.1016\/j.pupt.2024.102319_bib44","article-title":"Solid lipid nanoparticles (SLN'S)-trends and implications in drug targeting","volume":"1","author":"Sinha","year":"2010","journal-title":"Int. J. Adv. Pharmaceut. Sci."},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/pharmaceutics10040191","article-title":"Solid lipid nanoparticles: emerging colloidal nano drug delivery systems","volume":"10","author":"Mishra","year":"2018","journal-title":"Pharmaceutics"},{"issue":"20","key":"10.1016\/j.pupt.2024.102319_bib46","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.3390\/molecules25204781","article-title":"Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method","volume":"25","author":"Duong","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.pupt.2024.102319_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.nano.2010.10.007","article-title":"Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro","volume":"7","author":"Beck-Broichsitter","year":"2011","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art","volume":"86","author":"Weber","year":"2014","journal-title":"Eur. J. Pharm. Biopharm.: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"issue":"9","key":"10.1016\/j.pupt.2024.102319_bib49","first-page":"999","article-title":"Nanostructured lipid carriers (NLCs) as drug delivery platform: advances in formulation and delivery strategies","volume":"29","author":"Elmowafy","year":"2021","journal-title":"Saudi Pharmaceut. J.: SPJ: the official publication of the Saudi Pharmaceutical Society"},{"issue":"1\u20132","key":"10.1016\/j.pupt.2024.102319_bib50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijpharm.2018.05.070","article-title":"Nanostructured lipid carriers-based drug delivery for treating various lung diseases: a State-of-the-Art Review","volume":"547","author":"Patil","year":"2018","journal-title":"International journal of pharmaceutics"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib51","first-page":"46","article-title":"Design and evaluation of miconazole nitrate loaded nanostructured lipid carriers (NLC) for improving the antifungal therapy","volume":"3","author":"Sanap","year":"2013","journal-title":"J. Appl. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib52","article-title":"Nano-lipid carriers for topical application: current scenario","volume":"10","author":"Purohit","year":"2016","journal-title":"Asian J. Pharm."},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/03639045.2011.650648","article-title":"Preparation of Coenzyme Q10 nanostructured lipid carriers for epidermal targeting with high-pressure microfluidics technique","volume":"39","author":"Chen","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.pupt.2024.102319_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2010.05.005","article-title":"Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability","volume":"394","author":"Zhuang","year":"2010","journal-title":"International journal of pharmaceutics"},{"issue":"41","key":"10.1016\/j.pupt.2024.102319_bib55","doi-asserted-by":"crossref","DOI":"10.1088\/0953-8984\/18\/41\/R01","article-title":"Nanoemulsions: formation, structure, and physical properties","volume":"18","author":"Mason","year":"2006","journal-title":"J. Phys. Condens. Matter"},{"key":"10.1016\/j.pupt.2024.102319_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2017.03.008","article-title":"Nanoemulsion: concepts, development and applications in drug delivery","volume":"252","author":"Singh","year":"2017","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"issue":"6","key":"10.1016\/j.pupt.2024.102319_bib57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/nano9060821","article-title":"Current applications of nanoemulsions in cancer therapeutics","volume":"9","author":"S\u00e1nchez-L\u00f3pez","year":"2019","journal-title":"Nanomaterials"},{"issue":"10","key":"10.1016\/j.pupt.2024.102319_bib58","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1007\/s12274-018-2152-3","article-title":"Strategies to improve micelle stability for drug delivery","volume":"11","author":"Lu","year":"2018","journal-title":"Nano Res."},{"key":"10.1016\/j.pupt.2024.102319_bib59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jconrel.2017.11.049","article-title":"Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: formulation development, stability issues, basic considerations and applications","volume":"270","author":"Rai","year":"2018","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"issue":"3","key":"10.1016\/j.pupt.2024.102319_bib60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3746\/pnf.2019.24.3.225","article-title":"Techniques for formulation of nanoemulsion drug delivery system: a review","volume":"24","author":"Kumar","year":"2019","journal-title":"Preventive nutrition and food science"},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ceat.200406111","article-title":"High\u2010pressure homogenization as a process for emulsion formation","volume":"27","author":"Schultz","year":"2004","journal-title":"Chem. Eng. Technol.: Industrial Chemistry\u2010Plant Equipment\u2010Process Engineering\u2010Biotechnology"},{"issue":"28","key":"10.1016\/j.pupt.2024.102319_bib62","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1021\/acs.langmuir.7b01104","article-title":"A general route for nanoemulsion synthesis using low-energy methods at constant temperature","volume":"33","author":"Gupta","year":"2017","journal-title":"Langmuir : the ACS journal of surfaces and colloids"},{"key":"10.1016\/j.pupt.2024.102319_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2020.102344","article-title":"Emulsification and emulsion stability: the role of the interfacial properties","volume":"288","author":"Ravera","year":"2021","journal-title":"Adv. Colloid Interface Sci."},{"issue":"7","key":"10.1016\/j.pupt.2024.102319_bib64","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3109\/10837450.2015.1078353","article-title":"Anti-inflammatory effects of eugenol nanoemulsion as a topical delivery system","volume":"21","author":"Esmaeili","year":"2016","journal-title":"Pharmaceut. Dev. Technol."},{"key":"10.1016\/j.pupt.2024.102319_bib65","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.biopha.2017.04.020","article-title":"The therapeutic effect of nano-encapsulated and nano-emulsion forms of carvacrol on experimental liver fibrosis","volume":"90","author":"Hussein","year":"2017","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"issue":"8","key":"10.1016\/j.pupt.2024.102319_bib66","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/nn800275r","article-title":"Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform","volume":"2","author":"Zhang","year":"2008","journal-title":"ACS Nano"},{"issue":"3 Pt A","key":"10.1016\/j.pupt.2024.102319_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","article-title":"Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review","volume":"85","author":"Hadinoto","year":"2013","journal-title":"Eur. J. Pharm. Biopharm.: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"issue":"7","key":"10.1016\/j.pupt.2024.102319_bib68","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1039\/C4BM00427B","article-title":"Lipid-coated polymeric nanoparticles for cancer drug delivery","volume":"3","author":"Krishnamurthy","year":"2015","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.pupt.2024.102319_bib69","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/IJN.S198353","article-title":"Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives","volume":"14","author":"Mukherjee","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.pupt.2024.102319_bib70","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.mimet.2019.03.017","article-title":"Lipid-polymer hybrid nanoparticles: synthesis strategies and biomedical applications","volume":"160","author":"Dave","year":"2019","journal-title":"J. Microbiol. Methods"},{"key":"10.1016\/j.pupt.2024.102319_bib71","article-title":"Niosomes: a review on niosomal research in the last decade","volume":"56","author":"Bhardwaj","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.pupt.2024.102319_bib72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejpb.2019.08.015","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): fabrication, characterization, pharmaceutical and cosmetic applications","volume":"144","author":"Chen","year":"2019","journal-title":"Eur. J. Pharm. Biopharm.: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib73","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10717544.2013.838077","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations","volume":"21","author":"Abdelkader","year":"2014","journal-title":"Drug Deliv."},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib74","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.2042-7158.1985.tb05051.x","article-title":"The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice","volume":"37","author":"Azmin","year":"1985","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.pupt.2024.102319_bib75","series-title":"Nanomaterials and Nanosystems for Biomedical Applications","author":"Mozafari","year":"2007"},{"issue":"11","key":"10.1016\/j.pupt.2024.102319_bib76","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/17425247.2019.1663821","article-title":"Do niosomes have a place in the field of drug delivery?","volume":"16","author":"Muzzalupo","year":"2019","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.pupt.2024.102319_bib77","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2014.04.015","article-title":"Nano-niosomes as nanoscale drug delivery systems: an illustrated review","volume":"185","author":"Moghassemi","year":"2014","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"key":"10.1016\/j.pupt.2024.102319_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.supflu.2020.104984","article-title":"Sustainable technologies for liposomes preparation","volume":"165","author":"Maja","year":"2020","journal-title":"J. Supercrit. Fluids"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/21691401.2014.909822","article-title":"Nanostructured lipid carriers and their current application in targeted drug delivery","volume":"44","author":"Jaiswal","year":"2016","journal-title":"Artif. Cell Nanomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib80","doi-asserted-by":"crossref","first-page":"122","DOI":"10.30750\/ijpbr.2.1.19","article-title":"Nanoemulsion: a review on novel profusion in advanced drug delivery","volume":"2","author":"Bhosale","year":"2014","journal-title":"Indian J. Pharmaceut. Biol. Res."},{"issue":"8","key":"10.1016\/j.pupt.2024.102319_bib81","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.drudis.2017.05.015","article-title":"Lipid-polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges","volume":"22","author":"Bose","year":"2017","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.pupt.2024.102319_bib82","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Materials Au"},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib83","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41578-021-00281-4","article-title":"Let's talk about lipid nanoparticles","volume":"6","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.pupt.2024.102319_bib84","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13205-014-0214-0","article-title":"Nanoemulsion: an advanced mode of drug delivery system","volume":"5","author":"Jaiswal","year":"2015","journal-title":"3 Biotech."},{"issue":"10","key":"10.1016\/j.pupt.2024.102319_bib85","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/nano12101683","article-title":"Fish oil nanoemulsion supplementation attenuates bleomycin-induced pulmonary fibrosis BALB\/c mice","volume":"12","author":"Galdino de Souza","year":"2022","journal-title":"Nanomaterials"},{"issue":"8","key":"10.1016\/j.pupt.2024.102319_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103676","article-title":"Perfluorocarbon nanoemulsions enhance therapeutic siRNA delivery in the treatment of pulmonary fibrosis","volume":"9","author":"Ding","year":"2022","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.pupt.2024.102319_bib87","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/pharmaceutics13040486","article-title":"Inhalable jojoba oil dry nanoemulsion powders for the treatment of lipopolysaccharide- or H2O2-induced acute lung injury","volume":"13","author":"Zhang","year":"2021","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.pupt.2024.102319_bib88","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1208\/s12249-020-01798-7","article-title":"Dual asymmetric centrifugation efficiently produces a poloxamer-based nanoemulsion gel for topical delivery of pirfenidone","volume":"21","author":"Chung","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.pupt.2024.102319_bib89","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jconrel.2022.10.045","article-title":"Inhaled deep eutectic solvent based-nanoemulsion of pirfenidone in idiopathic pulmonary fibrosis","volume":"352","author":"Kang","year":"2022","journal-title":"J. Contr. Release : official journal of the Controlled Release Society"},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib90","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejpb.2012.11.023","article-title":"Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2","volume":"84","author":"Ivanova","year":"2013","journal-title":"Eur. J. Pharm. Biopharm.: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib91","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajps.2017.08.005","article-title":"Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Chennakesavulu","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.pupt.2024.102319_bib92","article-title":"Engineering of stimulus-responsive pirfenidone liposomes for pulmonary delivery during treatment of idiopathic pulmonary fibrosis","volume":"13","author":"Han","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.pupt.2024.102319_bib93","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/pharmaceutics13111851","article-title":"Aerosol delivery of surfactant liposomes for management of pulmonary fibrosis: an approach supporting pulmonary mechanics","volume":"13","author":"Kotta","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pupt.2024.102319_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613907","article-title":"Macrophage-targeted lung delivery of dexamethasone improves pulmonary fibrosis therapy via regulating the immune microenvironment","volume":"12","author":"Sang","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.pupt.2024.102319_bib95","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.7150\/thno.48152","article-title":"Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis","volume":"11","author":"Pan","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.pupt.2024.102319_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123644","article-title":"Nintedanib solid lipid nanoparticles improve oral bioavailability and ameliorate pulmonary fibrosis in vitro and in vivo models","volume":"649","author":"Kaur","year":"2024","journal-title":"International journal of pharmaceutics"},{"issue":"3","key":"10.1016\/j.pupt.2024.102319_bib97","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1166\/jbn.2015.1925","article-title":"Intracellular uptake of curcumin-loaded solid lipid nanoparticles exhibit anti-inflammatory activities superior to those of curcumin through the NF-\u03baB signaling pathway","volume":"11","author":"Wang","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib98","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s10753-013-9779-8","article-title":"Pharmacokinetic and anti-inflammatory effects of sanguinarine solid lipid nanoparticles","volume":"37","author":"Li","year":"2014","journal-title":"Inflammation"},{"key":"10.1016\/j.pupt.2024.102319_bib99","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"issue":"6","key":"10.1016\/j.pupt.2024.102319_bib100","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.nano.2017.04.005","article-title":"Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s)","volume":"13","author":"Garbuzenko","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.pupt.2024.102319_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2024.05.026","article-title":"Phospholipids of inhaled liposomes determine the in vivo fate and therapeutic effects of salvianolic acid B on idiopathic pulmonary fibrosis","volume":"371","author":"Peng","year":"2024","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib102","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12951-022-01435-4","article-title":"ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling","volume":"20","author":"Liu","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"14","key":"10.1016\/j.pupt.2024.102319_bib103","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.3390\/ijms22147743","article-title":"Liposomes loaded with everolimus and coated with hyaluronic acid: a promising approach for lung fibrosis","volume":"22","author":"Pandolfi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.pupt.2024.102319_bib104","doi-asserted-by":"crossref","DOI":"10.4238\/gmr.15027309","article-title":"Atomized paclitaxel liposome inhalation treatment of bleomycin-induced pulmonary fibrosis in rats","volume":"15","author":"Zhou","year":"2016","journal-title":"Genet. Mol. Res.: GMR"},{"issue":"5","key":"10.1016\/j.pupt.2024.102319_bib105","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1021\/acs.molpharmaceut.0c00026","article-title":"Inhalation of tetrandrine-hydroxypropyl-\u03b2-cyclodextrin inclusion complexes for pulmonary fibrosis treatment","volume":"17","author":"Su","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.pupt.2024.102319_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120761","article-title":"Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis","volume":"271","author":"Sun","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.pupt.2024.102319_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2024.100980","article-title":"Niclosamide - encapsulated lipid nanoparticles for the reversal of pulmonary fibrosis","volume":"25","author":"Yu","year":"2024","journal-title":"Materials today. Bio"},{"issue":"16","key":"10.1016\/j.pupt.2024.102319_bib108","first-page":"20260","article-title":"Co-delivery of astaxanthin and siTGF-\u03b21 via ionizable liposome nanoparticles for improved idiopathic pulmonary fibrosis therapy","volume":"16","author":"Cao","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"11","key":"10.1016\/j.pupt.2024.102319_bib109","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s11427-022-2314-8","article-title":"Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization. Science China","volume":"66","author":"Yan","year":"2023","journal-title":"Life Sci."},{"issue":"22","key":"10.1016\/j.pupt.2024.102319_bib110","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162831","article-title":"Liposomal UHRF1 siRNA shows lung fibrosis treatment potential through regulation of fibroblast activation","volume":"7","author":"Cheng","year":"2022","journal-title":"JCI insight"},{"issue":"1","key":"10.1016\/j.pupt.2024.102319_bib111","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/s12967-022-03740-w","article-title":"Targeted delivery of ZNF416 siRNA-loaded liposomes attenuates experimental pulmonary fibrosis","volume":"20","author":"Cheng","year":"2022","journal-title":"J. Transl. Med."},{"issue":"6\u20137","key":"10.1016\/j.pupt.2024.102319_bib112","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/01902148.2017.1354946","article-title":"Treatment of pulmonary fibrosis with siRNA against a collagen-specific chaperone HSP47 in vitamin A-coupled liposomes","volume":"43","author":"Otsuka","year":"2017","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.pupt.2024.102319_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106370","article-title":"Lipid nanoparticle-mediated mRNA delivery in lung fibrosis","volume":"183","author":"Massaro","year":"2023","journal-title":"Eur. J. Pharmaceut. Sci. : official journal of the European Federation for Pharmaceutical Sciences"},{"issue":"6","key":"10.1016\/j.pupt.2024.102319_bib114","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.nano.2018.05.005","article-title":"Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis","volume":"14","author":"Ding","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"11","key":"10.1016\/j.pupt.2024.102319_bib115","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/pharmaceutics13111983","article-title":"Delivery of pDNA to the lung by lipopolyplexes using N-lauroylsarcosine and effect on the pulmonary fibrosis","volume":"13","author":"Kurosaki","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455392400035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109455392400035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:28:32Z","timestamp":1733866112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109455392400035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":115,"alternative-id":["S109455392400035X"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2024.102319","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticles for pulmonary fibrosis: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2024.102319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102319"}}